Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

4 and 8 mg Ondansetron RapidFilm

APR Applied Pharma Research S.A.
4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water

Mechanism of action

Ondansetron RapidFilm is a novel proprietary formulation consisting of a polimeric film strip dissolving quickly wihtout any need of water and releasing the drug in the oral cavity.

Full description

Under the terms of the Joint Venture Agreement between the two drug delivery companies APR Applied Pharma Research s.a. of Switzerland (APR) and Labtec GmbH of Germany (Labtec) an Ondansetron RapidFilm is currently under final development.

APR and Labtec are currently comleting full development of a new oral formulation, generic to ZOFRAN® Zydis Lingual ODT (Oral Dispersible Tablet) marketed in Europe as well as in the US by Glaxo Smith Kline. It uses the proprietary RapidFilm® technology which is a novel, non-mucoadhesive, fast dissolving oral dosage form based on a water soluble polymer. The film disintegrates rapidly within seconds in contact with saliva, releases the drug in the oral cavity and promotes gastrointestinal absorption which is comparable to immediate release oral solid dosage forms. The RapidFilm® dosage form was especially designed for higher patient compliance. The application is easy. The patient does not face any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea.

The product is packed in a specially designed proprietary packaging system named RapidCard.

Dossier completion and submission is expected in Q3/2007; approval is expected sometime in 2008. The product will be registered as generic of Zofran ODT.

Internal evaluations suggests that RapidFilm can offer multiple competitive advantages over Zydis technology such as manufacturing costs, innovation, etc. so enabling RapidFilm to even successfully compete in a generic environment.

Development status

Phase II

Patent information

Patent Pending on either technology and packaging

Type of business relationship sought

Ondansetron RapidFilm is available for Licensing wherever Ondansetron is off-patent. We are looking for licensing Ondasetron RapidFilm at European or Worldwide level.

Licensing contact

Mr Paolo Galfetti
CEO
Request more information

More information

For more information about the product please visit website.

Company details

APR Applied Pharma Research S.A.
APR is a Swiss based R&D company offering innovative patent protected products for out-licensing as well as integrated and centrally managed R&D services on a contract basis.

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Partnering consultation free of charge
Need competitive intelligence information
Therapeutic Area Partnerships
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us